Centre of excellence

The Valens Company Announces Next Step Towards Nasdaq Listing

Retrieved on: 
Monday, November 15, 2021
OTC Bulletin Board, Centre of excellence, CBD, Compliance, Toronto Stock Exchange, Center, Valens (company), Health, Australia, CEO, Ownership, Shareholder, Computershare, SEDAR, Growth, Letter, COVID-19, Multimedia, Research, Forward-looking statement, CUSIP, Indian stock exchange, Intention, Common, Partnership, Board, TSX, ISIN, Company, Disclosure, Stock, Green Road railway station, Letter of transmittal, Consolidation, Cannabis, Risk, Security (finance), Online shopping, Risk management

KELOWNA, BC, Nov. 15, 2021 /PRNewswire/ -(TSX: VLNS) (OTCQX: VLNCF) (the "Company," "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, today announced that as the next step in its Nasdaq listing process, it will be completing a three for one consolidation (the "Consolidation") of its common shares ("Common Shares") on November 16, 2021 in order to meet Nasdaq listing requirements.

Key Points: 
  • KELOWNA, BC, Nov. 15, 2021 /PRNewswire/ -(TSX: VLNS) (OTCQX: VLNCF) (the "Company," "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, today announced that as the next step in its Nasdaq listing process, it will be completing a three for one consolidation (the "Consolidation") of its common shares ("Common Shares") on November 16, 2021 in order to meet Nasdaq listing requirements.
  • "This announcement represents a milestone towards the listing of Valens' Common Shares on Nasdaq," said Tyler Robson, CEO of The Valens Company.
  • The board of directors of Valens (the "Board") believes the Consolidation will result in a number of potential benefits to Valens, particularly in connection with the Company's application for a secondary listing of the Common Shares on Nasdaq.
  • To be accepted for listing on Nasdaq, the Company must meet certain minimum trading price requirements, which are anticipated to be satisfied as a result of the Consolidation.

The Valens Company Announces Strategic Distribution Agreement with APOTEKA SRL, part of GFI Costa Rica & Provides Australia Update

Retrieved on: 
Thursday, September 16, 2021
Stock, Forward-looking statement, Health, TGA, Company, Intention, Risk, GMP, Terpene, Centre of excellence, Center, Cannabis, Valens (company), Disclosure, Growth, COVID-19, Multimedia, MCT, AUS, Partnership, Dominican Republic, Compliance, Central, Research, TSX, Green Road railway station, Drug, Risk management

---

Key Points: 
  • Under the agreement, APOTEKA will bring Valens' nance brand, with future plans to include the Green Roads brand, into three core Central American markets: Costa Rica, the Dominican Republic and Panama.
  • Tyler Robson, Chief Executive Officer and Chair of The Valens Company, said, "This partnership with APOTEKA, part of GFI Costa Rica a multiregional conglomerate with a 45-year track record, is consistent with our distribution first, asset light, growth model in international markets.
  • The partnership represents a strategic expansion into Central America where APOTEKA will be distributing these products into regions including: Costa Rica, the Dominican Republic and Panama.
  • Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.